chufangao/CTO huggingface dataset:
Clinical trial NCT03946800: A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors
Official title: A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination With Durvalumab in Subjects With Advanced Solid Tumors
Sponsor: MedImmune LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 61.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-08
Primary completion date: 2023-08-24
Completion date: 2023-08-24
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:~https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT03556020: Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
Official title: A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Acronym: VIP
Sponsor: PhaseBio Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated: Study drug resupply delayed (Covid-19)
Enrollment: 35.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-15
Primary completion date: 2022-01-07
Completion date: 2022-01-07
Clinical trial NCT05764915: A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors
Official title: A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of RGT-264 Phosphate Tablets in Subjects With Advanced Solid Tumors
Sponsor: Regor Pharmaceuticals Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Due to the change in study plan and not due to safety reasons
Enrollment: 11.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-02-15
Primary completion date: 2024-02-20
Completion date: 2024-02-20
Plan to share individual participant data: NO
Clinical trial NCT04713592: Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
Official title: IMMprint: A Phase 3b Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating Safety and Efficacy of Risankizumab Compared to Placebo in Adult Subjects With Moderate to Severe Plaque Psoriasis With Palmoplantar (Non-Pustular) Involvement (PPPsO)
Acronym: IMMprint
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 174.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-26
Primary completion date: 2023-04-20
Completion date: 2023-04-20
Baseline population: Intent to Treat Population: all randomized participants, analyzed according to the treatment groups to which they were randomized during the Double-blind Period
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT03429543: Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
Official title: A Double-blind, Randomised, Placebo-controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Empagliflozin and Linagliptin Over 26 Weeks, With a Double-blind Active Treatment Safety Extension Period up to 52 Weeks, in Children and Adolescents With Type 2 Diabetes Mellitus
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 175.0 (ACTUAL)
Number of arms: 7.0
Start date: 2018-03-20
Primary completion date: 2022-10-19
Completion date: 2023-05-31
Baseline population: The randomised set (RS) included all randomised patients, regardless whether they took trial medication
Plan to share individual participant data: YES
IPD sharing description: After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement.~Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.~The data shared are the raw clinical study data sets.
IPD time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Clinical trial NCT02937454: Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency
Official title: A Randomised, Double-Blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Failure (Affirm-AHF)
Acronym: Affirm-AHF
Sponsor: Vifor Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 1132.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-03
Primary completion date: 2020-07-21
Completion date: 2020-07-21
Plan to share individual participant data: NO
Clinical trial NCT04064346: Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
Official title: A Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants With Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-label Phase: The ACTION Study
Acronym: ACTION
Sponsor: Palladio Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The decision is based on a thorough reassessment of the commercial potential of lixivaptan as a potential best-in-class therapy for patients with autosomal dominant polycystic kidney disease (ADPKD).
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-28
Primary completion date: 2022-08-03
Completion date: 2022-08-03
Plan to share individual participant data: NO
Clinical trial NCT03333148: Preoperative Oral ImmunoNuTrition to Improve Surgical Outcomes for IBD Patients (PINT)
Official title: Preoperative Oral ImmunoNuTrition to Improve Surgical Outcomes for Inflammatory Bowel Disease Patients (PINT): A Randomized Controlled Trial
Acronym: PINT
Sponsor: University of Alabama at Birmingham (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: never enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-01
Primary completion date: 2021-06-01
Completion date: 2022-01-01
Clinical trial NCT02989129: Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients
Official title: Prospective Open Labeled Pilot Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: FDA IND Approval
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-04-30
Primary completion date: 2020-04-30
Completion date: 2020-04-30
Clinical trial NCT03945019: CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
Official title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease
Sponsor: Celltrion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 396.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-28
Primary completion date: 2022-08-23
Completion date: 2023-08-22
Baseline population: All-randomized population
Clinical trial NCT02815995: Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Official title: A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 56.0 (ACTUAL)
Number of arms: 6.0
Start date: 2016-08-16
Primary completion date: 2024-06-17
Completion date: 2024-06-17
Clinical trial NCT04123574: A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
Official title: A Pilot Proof of Mechanism Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPPs), in Patients With Pancreatic Cancer
Sponsor: BioXcel Therapeutics Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: No longer relevant to field
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-15
Primary completion date: 2021-12-06
Completion date: 2021-12-06
Plan to share individual participant data: NO
Clinical trial NCT04436458: Niclosamide In Moderate COVID-19
Official title: Phase 2, Multicentre, Randomized, Double Blind, 2 Arms Placebo-controlled Study in Adults With Moderate COVID-19 With Gastrointestinal Signs and Symptoms
Sponsor: Entero Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor asset acquired by another pharma company who opened their own IND for this compound. First Wave Bio never started this study in the US or ex-US.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-20
Primary completion date: 2022-01-20
Completion date: 2022-01-20
Clinical trial NCT04392128: Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)
Official title: Randomised, Double-blind, Placebo-controlled Phase 2 Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies
Acronym: HYACINTHE
Sponsor: Institut de cancérologie Strasbourg Europe (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: competent authority decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-02
Primary completion date: 2020-09-02
Completion date: 2020-09-02
Plan to share individual participant data: NO
Clinical trial NCT04018313: To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects
Official title: A Phase 1, Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of Three Formulations of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects
Sponsor: Celltrion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 176.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-05-28
Primary completion date: 2021-03-27
Completion date: 2021-04-30
Baseline population: ITT set: all subjects enrolled and randomly assigned to receive a dose of any study drug, regardless of whether or not any study drug was administered.
Clinical trial NCT03908827: BMAC in Severe Hip or Knee Osteoarthritis Awaiting Arthroplasty
Official title: The Effectiveness of Bone Marrow Aspirate Concentrate (BMAC) in Patients With Severe Hip or Knee Osteoarthritis Awaiting Arthroplasty - A Randomized Controlled Trial
Sponsor: CAPRI Clinic (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Change of study design
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-31
Primary completion date: 2022-12-31
Completion date: 2023-03-31
Plan to share individual participant data: NO
Clinical trial NCT03360006: A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer
Official title: A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic Reasons
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-16
Primary completion date: 2020-12-19
Completion date: 2020-12-19
Plan to share individual participant data: NO
Clinical trial NCT04466826: Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients
Official title: Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Low enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-02
Primary completion date: 2021-02-05
Completion date: 2021-02-05
Clinical trial NCT03635489: A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Official title: A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin Paclitaxel Plus Concurrent and Extended Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated, Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 100.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-15
Primary completion date: 2021-05-26
Completion date: 2023-05-11
Clinical trial NCT05204160: Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Official title: Phase II Study of Pembrolizumab as Salvage Therapy Among Multiple Myeloma Patients Progressing on CAR-T Cell Therapy
Sponsor: Emory University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: slow accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-04-11
Primary completion date: 2024-02-27
Completion date: 2024-02-27
Clinical trial NCT03286114: Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
Official title: Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab for Relapse of Primary Malignancy After Allogeneic Hematopoietic Stem Cell Transplant: A Feasibility Study
Sponsor: University of Michigan Rogel Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Lack of patient population
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-12-21
Primary completion date: 2020-10-22
Completion date: 2021-04-28
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02923739: Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Official title: A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated early by the Sponsor
Enrollment: 9.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-05
Primary completion date: 2022-09-27
Completion date: 2022-09-27
Baseline population: The study was terminated early by the sponsor
Clinical trial NCT03213457: A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
Official title: A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 681.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-07-07
Primary completion date: 2020-03-27
Completion date: 2023-12-06
Baseline population: Full Analysis Set: all randomized participants who received at least 1 dose of study drug.
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Clinical trial NCT02529475: Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)
Official title: Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)
Acronym: HYDROPS
Sponsor: University Hospital, Grenoble (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: recruitment problem-covid-
Enrollment: 25.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-02-01
Primary completion date: 2020-09-30
Completion date: 2020-09-30
Clinical trial NCT04459286: The Nitazoxanide Plus Atazanavir for COVID-19 Study
Official title: A Randomized, Open Label Trial to Investigate the Efficacy and Safety of Nitazoxanide Plus Atazanavir/Ritonavir for the Treatment of COVID-19: a Pilot Study
Acronym: NACOVID
Sponsor: Obafemi Awolowo University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: IDSMB recommendation
Enrollment: 57.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-10-09
Primary completion date: 2021-05-02
Completion date: 2021-05-02
Plan to share individual participant data: NO
Clinical trial NCT04566926: A Study of JNJ-64140284 in Healthy Male Participants
Official title: A 3-Part, Randomized, Placebo-controlled, Double-blind, Single Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Male Participants
Acronym: AMPAR
Sponsor: Janssen Pharmaceutica N.V., Belgium (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: business decision
Enrollment: 33.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-09-29
Primary completion date: 2021-04-05
Completion date: 2021-04-05
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT03377309: Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients
Official title: Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients
Sponsor: American University of Beirut Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study halted due to adverse events
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-01
Primary completion date: 2020-06-01
Completion date: 2021-07-01
Plan to share individual participant data: NO
Clinical trial NCT02322814: A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
Official title: A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor's decision
Enrollment: 169.0 (ACTUAL)
Number of arms: 4.0
Start date: 2015-03-12
Primary completion date: 2018-08-10
Completion date: 2021-09-17
Baseline population: The intent-to-treat (ITT) population was defined as all enrolled participants, whether or not the assigned study treatment was received.
Clinical trial NCT03202095: Creatine for Treatment of Depression Associated With Type 2 Diabetes
Official title: Creatine for Treatment of Depression Associated With Type 2 Diabetes
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: No referral from diabetes clinic.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-01
Primary completion date: 2024-06-10
Completion date: 2024-06-10
Plan to share individual participant data: NO